FSNUF - Fresenius SE & Co. KGaA

Other OTC - Other OTC Delayed Price. Currency in USD
81.23
+3.72 (+4.81%)
At close: 12:09PM EST
Stock chart is not supported by your current browser
Previous Close77.51
Open81.23
Bid0.00 x 0
Ask0.00 x 0
Day's Range81.23 - 81.23
52 Week Range75.20 - 87.78
Volume500
Avg. Volume117
Market Cap44.823B
Beta0.13
PE Ratio (TTM)20.66
EPS (TTM)3.93
Earnings DateN/A
Forward Dividend & Yield0.69 (0.89%)
Ex-Dividend Date2017-05-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters13 days ago

    Fresenius CFO backs acquisition course - Boersen-Zeitung

    FRANKFURT (Reuters) - German healthcare group Fresenius (FREG.DE) will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief ...

  • Reuters13 days ago

    Fresenius CFO backs acquisition course -Boersen-Zeitung

    German healthcare group Fresenius will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief as saying. Last year Fresenius ...

  • Drugmaker Warned Again for Ignoring Bad Quality Tests
    Bloomberg17 days ago

    Drugmaker Warned Again for Ignoring Bad Quality Tests

    U.S. regulators warned Fresenius SE last month that workers in one of its cancer-drug plants ignored tests that found the products made there weren’t meeting sterility standards.

  • Drugmaker Ignored More Than 200 Bad Quality Tests, FDA Says
    Bloomberg24 days ago

    Drugmaker Ignored More Than 200 Bad Quality Tests, FDA Says

    U.S. regulators warned Fresenius SE after the company’s Indian plant that makes cancer-drug ingredients for the U.S. market aborted hundreds of drug-quality tests because they seemed like they were going ...

  • Reuterslast month

    Fresenius now sees completion of Akorn takeover in early 2018

    Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday. "While we've been focused on a 2017 close, it's now clear that closing in early 2018 is more likely, and we're quite comfortable with this timeline," the spokesman said.

  • Fresenius SE & Co. KGaA :FSNUF-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
    Capital Cube2 months ago

    Fresenius SE & Co. KGaA :FSNUF-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017

    Categories: Yahoo FinanceGet free summary analysis Fresenius SE & Co. KGaA reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Fresenius SE & Co. KGaA – ResMed Inc. (RMD-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 9,746.44 million, Net Earnings ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to Fresenius SE & Co. KGaA : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Fresenius SE & Co. KGaA Here are 5 ETFs with the largest exposure to FSNUF-US. Comparing the performance and risk of Fresenius SE & Co. KGaA with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)

  • Here's Why You Should Offload Fresenius Medical Stock Now
    Zacks2 months ago

    Here's Why You Should Offload Fresenius Medical Stock Now

    Fresenius (FMS) grapples with multiple issues. An unfavorable estimate revision trend adds to the woes.

  • Reuters2 months ago

    Fresenius says Akorn deal closure could take until next year

    German healthcare group Fresenius SE (FREG.DE) said the planned takeover of Akorn (AKRX.O), a U.S. maker of liquid generic drugs, might not be completed before next year as the U.S. antitrust review could take longer than expected. Akorn's business has deteriorated since Fresenius struck the acquisition agreement in April, valuing the maker of medical creams, ophthalmic drugs and oral liquids at $4.75 billion (3.6 billion pounds). Akorn's operating income has slumped on supply disruptions and competition for a range of drugs.

  • Foreign Stock Roundup: Toyota, Gol Linhas Beat, AstraZeneca, Fresenius Miss
    Zacks2 months ago

    Foreign Stock Roundup: Toyota, Gol Linhas Beat, AstraZeneca, Fresenius Miss

    Earnings numbers continued to guide Europe's markets last week.

  • Fresenius Medical (FMS) Q3 Earnings Miss, FY17 View Intact
    Zacks2 months ago

    Fresenius Medical (FMS) Q3 Earnings Miss, FY17 View Intact

    Strong growth in Health Care Products and Health Care Services segments drove Fresenius's (FMS) third-quarter revenues. Lackluster performance by the renal pharmaceutical segment is a concern.

  • Capital Cube3 months ago

    Fresenius SE & Co. KGaA – Value Analysis (US OTC:FSNUF) : November 3, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Fresenius SE & Co. KGaA a score of 64. Our analysis is based on comparing Fresenius SE & Co. KGaA with the following peers – Pivot Pharmaceuticals Inc., Positron Corporation, Paradigm Medical Industries, Inc. and Annidis Corporation (PVOTF-US, POSC-US, PDMI-US and RHA-CA). Investment Outlook Fresenius SE & ... Read more (Read more...)

  • Fresenius SE & Co. KGaA breached its 50 day moving average in a Bearish Manner : FSNUF-US : November 2, 2017
    Capital Cube3 months ago

    Fresenius SE & Co. KGaA breached its 50 day moving average in a Bearish Manner : FSNUF-US : November 2, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Fresenius SE & Co. KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Reuters3 months ago

    Fresenius says Akorn troubles could continue into next year

    German healthcare group Fresenius SE said on Thursday that weakness at Akorn , the U.S. maker of liquid generic drugs it has agreed to buy, could continue into next year but the deal was still worth it over the longer term. The 2018 targets for Akorn, which Fresenius plans to take over at the end of this year, were "challenging", the diversified drugmaker said in presentation slides posted on its website after the release of its quarterly results.

  • Reuters3 months ago

    Fresenius adj EBIT up 11 pct on hospitals, drugs

    German healthcare group Fresenius said third-quarter adjusted net income gained 11 percent on higher drug sales and helped by the addition of Spanish hospitals chain Quironsalud. Quarterly net income adjusted ...

  • Reuters3 months ago

    Billionaire Insys founder charged in U.S. opioid bribe case

    The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic. John Kapoor, Insys' majority shareholder who stepped down as chief executive in January, was charged with engaging in conspiracies to commit racketeering, mail fraud and wire fraud in an indictment filed in federal court in Boston. Following a court hearing in Phoenix, Kapoor, 74, was released on a $1 million bond.

  • Fresenius SE & Co. KGaA breached its 50 day moving average in a Bullish Manner : FSNUF-US : October 17, 2017
    Capital Cube3 months ago

    Fresenius SE & Co. KGaA breached its 50 day moving average in a Bullish Manner : FSNUF-US : October 17, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Fresenius SE & Co. KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Reuters4 months ago

    Senvest Management shorting drug stocks Insys, Akorn, Fresenius

    New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday, Speaking at the Sohn Conference ...

  • Fresenius SE & Co. KGaA breached its 50 day moving average in a Bullish Manner : FSNUF-US : September 8, 2017
    Capital Cube4 months ago

    Fresenius SE & Co. KGaA breached its 50 day moving average in a Bullish Manner : FSNUF-US : September 8, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Fresenius SE & Co. KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Fresenius SE & Co. KGaA breached its 50 day moving average in a Bullish Manner : FSNUF-US : August 28, 2017
    Capital Cube5 months ago

    Fresenius SE & Co. KGaA breached its 50 day moving average in a Bullish Manner : FSNUF-US : August 28, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Fresenius SE & Co. KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • BioScrip (BIOS) Shows Strength: Stock Adds 6.6% in Session
    Zacks5 months ago

    BioScrip (BIOS) Shows Strength: Stock Adds 6.6% in Session

    BioScrip, Inc. (BIOS) moved big last session, as its shares jumped almost 7% on the day.

  • Fresenius SE & Co. KGaA :FSNUF-US: Earnings Analysis: Q2, 2017 By the Numbers : August 9, 2017
    Capital Cube5 months ago

    Fresenius SE & Co. KGaA :FSNUF-US: Earnings Analysis: Q2, 2017 By the Numbers : August 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Fresenius SE & Co. KGaA reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 9,397.00 million, Net Earnings of USD 495.62 million. Gross margins narrowed from 32.17% to 30.95% compared to the same period last year, operating (EBITDA) margins now 17.64% from 18.85%. Change ... Read more (Read more...)

  • Fresenius Medical Inks $2B Deal to Take Over NxStage Medical
    Zacks5 months ago

    Fresenius Medical Inks $2B Deal to Take Over NxStage Medical

    Fresenius Medical's (FMS) latest development is expected to fortify the company's foothold in the Home dialysis market, particularly in the renal care space.